Drug intelligence / Profile preview

VIR-201

Development stage: Phase 2
Lead developer: Vir Biotechnology
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

VIR-201 is a code that appears to refer to a sub-protocol (VIR-SHB1-V201) within the PREVAIL platform trial, a Phase 2 clinical study conducted by Vir Biotechnology. This study investigates regimens for chronic Hepatitis B infection, primarily involving the investigational drugs VIR-3434 and VIR-2218. VIR-3434 is an HBV-neutralizing monoclonal antibody, while VIR-2218 is an HBV-targeting small interfering ribonucleic acid (siRNA). The study aims to evaluate the safety and efficacy of these agents, sometimes in combination with other therapies like pegylated interferon alpha (PEG-IFNα) and nucleotide reverse transcriptase inhibitors (NRTIs), to achieve a functional cure for chronic HBV. Other codes like 'VB-201' (an oxidized phospholipid small molecule from VBL Therapeutics) and 'VG201' (an oncolytic virus from Virogin) exist, and 'VIR-2020' is another preclinical program from Vir Biotechnology, highlighting the non-specificity of 'VIR-201' as a standalone drug name.

Other names: VIR-SHB1-V201 (STRIVE) Sub-Protocol A

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on VIR-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIR-201.

Explore the full profile